{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T22:13:09Z","timestamp":1654035189119},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"Supplement_C","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this study was to evaluate the effects on the adherence of drug prescription to the guideline recommendations of a chronic care model based on the close interaction between hospital and local healthcare district cardiologists through a shared web-based database. From 2018 to 2021, patients hospitalized for an episode of acute decompensated heart failure (HF) (de novo or worsening) in cardiology wards from the healthcare district of Bari, Italy, were enrolled. The follow-up programme was based on a first visit after discharge within 1\u2009month; patients were therefore addressed to the local health district cardiologist outpatient clinics when not requiring further invasive investigations and haemodynamically stable and followed-up with at least one visit every 6 months. In order to share in-hospital patients\u2019 data with outpatient clinics, at discharge, they were entered in a web-based database accessible for all cardiologists and centres participating in the Ponte Project. The group of patients affected by HF with reduced ejection fraction (HFrEF) were considered for the analyses. Drug prescription rates at 1-year follow-up were analysed as endpoint, as well as the re-admission for HF worsening. Out of 1200 HF patients enrolled in the project until December 2021, 56% were affected by HFrEF. At 1-year follow-up, 91% of patients were assuming beta-blockers, 86% mineralocorticoid receptor antagonists, 98% angiotensin-converting enzyme inhibitors\/angiotensin receptor antagonists\/neprilysin angiotensin receptor antagonists, and 13% ARNI. Compared to patients enrolled before 2020, ARNI prescription increased in 2021 (60% vs. 13%, respectively, P\u2009&amp;lt;\u20090.001). In 30% of patients, ARNI were prescribed before hospital discharge. Furthermore, in 10% of the population (most diabetics), sodium-glucose cotransporter 2 inhibitors were also prescribed. The implementation of the PONTE project was associated with an improved adherence to guidelines recommendations.<\/jats:p>","DOI":"10.1093\/eurheartj\/suac019","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T06:53:16Z","timestamp":1652943196000},"page":"C221-C224","source":"Crossref","is-referenced-by-count":0,"title":["The PONTE (<u>P<\/u>DTA FOR INTEGRATED F<u>O<\/u>LLOW-UP TERRITORY HOSPITAL OF THE PATIE<u>N<\/u>T WITH CARDIAC HEAR<u>T<\/u> FAILUR<u>E<\/u>) (BRIDGE) Heart Failure project: increased adherence to guideline-recommended therapies through web-based shared clinical database"],"prefix":"10.1093","volume":"24","author":[{"given":"Luisa","family":"De Gennaro","sequence":"first","affiliation":[{"name":"San Paolo Hospital Bari , Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Iacoviello","sequence":"additional","affiliation":[{"name":"Department of Medical & Surgical Sciences, University of Foggia , Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Donadeo","sequence":"additional","affiliation":[{"name":"San Paolo Hospital Bari , Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"San Paolo Hospital Bari , Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natale Daniele","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Department of Medical & Surgical Sciences, University of Foggia , Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Caldarola","sequence":"additional","affiliation":[{"name":"San Paolo Hospital Bari , Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2022053121522832300_suac019-B1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2022053121522832300_suac019-B2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022053121522832300_suac019-B3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2022053121522832300_suac019-B4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022053121522832300_suac019-B5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2022053121522832300_suac019-B6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022053121522832300_suac019-B7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022053121522832300_suac019-B8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCHEARTFAILURE.112.000161","article-title":"Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry","volume":"6","author":"Tavazzi","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2022053121522832300_suac019-B9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"21","author":"Kapelios","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022053121522832300_suac019-B10","doi-asserted-by":"crossref","first-page":"e009237","DOI":"10.1161\/JAHA.118.009237","article-title":"Characteristics and treatments of patients enrolled in the CHAMP-HF registry compared with patients enrolled in the PARADIGM-HF trial","volume":"7","author":"DeVore","year":"2018","journal-title":"Am Heart Assoc"},{"key":"2022053121522832300_suac019-B11","doi-asserted-by":"crossref","first-page":"e017765","DOI":"10.1136\/bmjopen-2017-017765","article-title":"Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review","volume":"8","author":"Shanbhag","year":"2018","journal-title":"BMJ Open"},{"key":"2022053121522832300_suac019-B12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ejhf.765","article-title":"Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis","volume":"19","author":"Van Spall","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022053121522832300_suac019-B13","first-page":"150","article-title":"Studio multicentrico APULIA HF: efficacia di un protocollo di gestione condiviso fra ospedale e territorio dei pazienti ospedalizzati per scompenso cardiaco acuto","volume":"18","author":"Iacoviello","year":"2017","journal-title":"G Ital Cardiol"},{"key":"2022053121522832300_suac019-B14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2022053121522832300_suac019-B15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_C\/C221\/43889341\/suac019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_C\/C221\/43889341\/suac019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T21:52:46Z","timestamp":1654033966000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/24\/Supplement_C\/C221\/6587930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":15,"journal-issue":{"issue":"Supplement_C","published-online":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suac019","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,5,1]]}}}